Topic: Vaccinology

Scientists at the University of Cambridge have developed "proactive vaccinology" technology designed to provide immunity against coronaviruses that have not yet emerged in humans. The research involves testing shots on mice to recognize pathogens currently found in bats. Critics argue this new terminology is a rebranding effort for gene therapy products that lack traditional manufacturer liability.

Dr. Robert Malone discusses the risks of antibody-dependent enhancement (ADE), a condition where vaccine-induced antibodies facilitate viral entry into cells rather than neutralizing the pathogen. Malone cites the 1960s pediatric RSV vaccine and Dengue fever as primary examples of this phenomenon. He expresses concern that current mass vaccination strategies may inadvertently trigger similar enhanced disease outcomes.